ARTICLE | Distillery Therapeutics
Neurology
December 20, 2016 7:38 PM UTC
Patient sample and mouse studies suggest miR-338-3p could help treat psychiatric symptoms in patients with 22q11.2 deletion syndrome. In a mouse model of the syndrome, injection of an adeno-associated...
BCIQ Company Profiles
BCIQ Target Profiles